Smoking as a risk factor for colorectal neoplasms in young individuals? A systematic meta-analysis.
Early-onset colorectal neoplasms
Risk factor
Smoking
Journal
International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899
Informations de publication
Date de publication:
06 May 2023
06 May 2023
Historique:
accepted:
10
04
2023
medline:
8
5
2023
pubmed:
6
5
2023
entrez:
5
5
2023
Statut:
epublish
Résumé
Early-onset colorectal neoplasms (EoCRN) include both benign and malign colorectal tumors, which occur before the age of 50. The incidence of EoCRN is rising worldwide. Tobacco smoking has previously been proven to be related to the development of various tumor types. However, its relationship with EoCRN is not clearly defined. Hence, we carried out a systematic review and a meta-analysis to evaluate the relationship between smoking status and the risk of EoCRN. A systematic search of PubMed, EMBASE, and Web of Science up to September 7, 2022, was performed for studies that evaluated the association of smoking status with EoCRN. The quality of the case-control study was evaluated with the Newcastle‒Ottawa Scale. The quality of the cross-sectional studies was evaluated with the American Health Care Research and Quality checklist. Fixed-effects models were used to pool odds ratios (ORs) to evaluate the relationship between the risk of developing EoCRN and smoking status. The meta-analyses were performed with Review Manager version 5.4, and funnel plots and publication bias tests were produced by STATA software. A total of six studies were included in this meta-analysis. After pooling the results of these six studies, we found that current smokers carry a relatively high risk of developing EoCRN (OR, 1.33; 95% confidence interval [CI], 1.17-1.52) compared to never-smokers. Ex-smokers were not at a significantly increased risk for developing EoCRN (OR, 1.00; 95% CI, 0.86-1.18). Smoking behavior is significantly associated with an increased risk for developing EoCRN and might be one of the reasons for the increasing incidence. Ex-smokers who quit are not at significant risk of developing EoCRN.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Early-onset colorectal neoplasms (EoCRN) include both benign and malign colorectal tumors, which occur before the age of 50. The incidence of EoCRN is rising worldwide. Tobacco smoking has previously been proven to be related to the development of various tumor types. However, its relationship with EoCRN is not clearly defined. Hence, we carried out a systematic review and a meta-analysis to evaluate the relationship between smoking status and the risk of EoCRN.
METHODS
METHODS
A systematic search of PubMed, EMBASE, and Web of Science up to September 7, 2022, was performed for studies that evaluated the association of smoking status with EoCRN. The quality of the case-control study was evaluated with the Newcastle‒Ottawa Scale. The quality of the cross-sectional studies was evaluated with the American Health Care Research and Quality checklist. Fixed-effects models were used to pool odds ratios (ORs) to evaluate the relationship between the risk of developing EoCRN and smoking status. The meta-analyses were performed with Review Manager version 5.4, and funnel plots and publication bias tests were produced by STATA software.
RESULTS
RESULTS
A total of six studies were included in this meta-analysis. After pooling the results of these six studies, we found that current smokers carry a relatively high risk of developing EoCRN (OR, 1.33; 95% confidence interval [CI], 1.17-1.52) compared to never-smokers. Ex-smokers were not at a significantly increased risk for developing EoCRN (OR, 1.00; 95% CI, 0.86-1.18).
DISCUSSION
CONCLUSIONS
Smoking behavior is significantly associated with an increased risk for developing EoCRN and might be one of the reasons for the increasing incidence. Ex-smokers who quit are not at significant risk of developing EoCRN.
Identifiants
pubmed: 37147435
doi: 10.1007/s00384-023-04405-w
pii: 10.1007/s00384-023-04405-w
pmc: PMC10163071
doi:
Types de publication
Systematic Review
Meta-Analysis
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
114Informations de copyright
© 2023. The Author(s).
Références
J Natl Cancer Inst. 2010 Jul 21;102(14):1012-22
pubmed: 20587792
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28376186
JAMA. 2017 Jan 24;317(4):388-406
pubmed: 28118455
J Cell Physiol. 2019 Feb;234(2):1369-1379
pubmed: 30076725
Am J Gastroenterol. 2017 Jul;112(7):1016-1030
pubmed: 28555630
J Thorac Oncol. 2021 Jun;16(6):968-979
pubmed: 33722709
J Pathol. 2017 Nov;243(3):366-375
pubmed: 28791728
Clin Cancer Res. 2018 May 1;24(9):2092-2099
pubmed: 29490987
N Engl J Med. 2016 Apr 28;374(17):1605-7
pubmed: 27119236
Environ Mol Mutagen. 2006 Aug;47(7):527-32
pubmed: 16721749
Methods Mol Biol. 2022;2345:41-65
pubmed: 34550583
Toxicol Lett. 2019 Dec 15;317:102-109
pubmed: 31574306
Tumour Biol. 2016 Jan;37(1):1349-56
pubmed: 26293897
BMC Med. 2019 Nov 27;17(1):213
pubmed: 31771596
Cancer Epidemiol. 2020 Dec;69:101828
pubmed: 32998071
JAMA. 2016 Jun 21;315(23):2595-609
pubmed: 27305518
Clin Gastroenterol Hepatol. 2019 Jan;17(1):115-122
pubmed: 30025922
Cancer Epidemiol Biomarkers Prev. 2019 Aug;28(8):1275-1282
pubmed: 31113868
Scand J Gastroenterol. 2016;51(6):731-8
pubmed: 26863602
Am J Pathol. 2001 Apr;158(4):1517-24
pubmed: 11290569
N Engl J Med. 2013 Sep 5;369(10):954-64
pubmed: 24004122
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Front Oncol. 2021 Oct 08;11:702322
pubmed: 34692479
Eur J Intern Med. 2021 May;87:36-43
pubmed: 33610414
PLoS One. 2013 Apr 08;8(4):e60777
pubmed: 23593308
BMJ. 2000 Jun 10;320(7249):1574-7
pubmed: 10845965
Breast Cancer Res. 2017 Nov 22;19(1):118
pubmed: 29162146
BMC Cancer. 2017 Dec 19;17(1):869
pubmed: 29258461
Cancer Metastasis Rev. 2018 Mar;37(1):173-187
pubmed: 29322354
PLoS Med. 2021 Mar 29;18(3):e1003583
pubmed: 33780438
Cancer Control. 2020 Jan-Dec;27(1):1073274820976670
pubmed: 33274652
Am J Gastroenterol. 2020 Dec;115(12):1940-1949
pubmed: 32773458
Am J Epidemiol. 2005 May 1;161(9):806-15
pubmed: 15840612
Gastroenterology. 2020 Aug;159(2):492-501.e7
pubmed: 31926997
Lancet. 2017 May 13;389(10082):1885-1906
pubmed: 28390697
Genet Epidemiol. 2016 Jul;40(5):356-65
pubmed: 27061572
J Gastroenterol Hepatol. 2017 Jan;32(1):98-105
pubmed: 27197805
Public Health Rep. 2016 Mar-Apr;131(2):229-32
pubmed: 26957656
Biochem Pharmacol. 2018 May;151:47-58
pubmed: 29501585
Clin Gastroenterol Hepatol. 2022 Jun;20(6):1229-1240.e5
pubmed: 33524598
Cytokine. 2022 Jan;149:155749
pubmed: 34739898
Clin Epidemiol. 2014 Apr 07;6:137-45
pubmed: 24741327
World J Gastroenterol. 2016 Mar 14;22(10):2981-92
pubmed: 26973394